Literature DB >> 12072226

Co-stimulation and modulation of the ensuing immune response.

C J Howard1, J C Hope, S A Stephens, D R Gliddon, G P Brooke.   

Abstract

As a consequence of the central role of dendritic cells (DC) in stimulating primary immune responses any bias in the response introduced by the DC has the potential for having a long-term effect on immunity. Examination and analysis of ruminant afferent lymph dendritic cells derived by cannulation allows studies on the properties of ex vivo DC that is not possible in humans and rodents and information can be derived from ruminants that has implications of generic relevance. Previous studies have identified two major populations of DC in afferent lymph draining the skin of cattle that differ in their capacity to stimulate CD4 and CD8 T cells. Differences in expression of cytokine transcripts have now been shown for the two types of DC. The CD11a(+)/SIRPalpha(-) population synthesised more IL-12, whilst the CD11a(-)/SIRPalpha(+) population produced more IL-10. This is likely to affect the bias of the immune response following presentation of antigen to T cells by one DC sub-population or the other. An inability to synthesise IL-1alpha was the reason for the failure of the CD11a(+)/SIRPalpha(-) DC to stimulate CD8 T cells. This property would potentially affect the induction of CD8 responses. Expression of the co-stimulatory molecules CD80, CD86 and CD40 appeared similar for both DC populations and not to relate to differences in function. A further examination of the SIRPalpha molecule on DC indicated that on cross-linking it was tyrosine phosphorylated and that it recruited the SHP-2 protein phosphatase. Associated with this was a blocking of TNFalpha secretion on exposure to LPS. The interaction of SIRPalpha with its ligand CD47 on T cells appeared to be an early event in the stimulation of T cells as binding of the ligand was reduced on activated T cells. CD26 was identified as another molecule expressed by the SIRPalpha(-) DC sub-population. This is reported to have an enzymatic activity on certain chemokines that could result in the promotion of a Th1 bias.A model is proposed that takes these observations into account in which SIRPalpha(-) DC would be expected to promote a Th1 biased response and the SIRPalpha(+) DC a more balanced one.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12072226     DOI: 10.1016/s0165-2427(02)00043-0

Source DB:  PubMed          Journal:  Vet Immunol Immunopathol        ISSN: 0165-2427            Impact factor:   2.046


  5 in total

1.  Study on biological characters of SGC7901 gastric cancer cell-dendritic cell fusion vaccines.

Authors:  Kun Zhang; Peng-Fen Gao; Pei-Wu Yu; Yun Rao; Li-Xin Zhou
Journal:  World J Gastroenterol       Date:  2006-06-07       Impact factor: 5.742

2.  Epigenetic Regulation of IFI44L Expression in Monocytes Affects the Functions of Monocyte-Derived Dendritic Cells in Systemic Lupus Erythematosus.

Authors:  Shuaihantian Luo; Ruifang Wu; Qianwen Li; Guiying Zhang
Journal:  J Immunol Res       Date:  2022-05-10       Impact factor: 4.493

3.  Coating of mannan on LPD particles containing HPV E7 peptide significantly enhances immunity against HPV-positive tumor.

Authors:  Zhengrong Cui; Su-Ji Han; Leaf Huang
Journal:  Pharm Res       Date:  2004-06       Impact factor: 4.200

4.  Subset-Specific Expression of Toll-Like Receptors by Bovine Afferent Lymph Dendritic Cells.

Authors:  Dirk Werling; Jayne C Hope; Nazneen Siddiqui; Stephanie Widdison; Chris Russell; Paul Sopp; Tracey J Coffey
Journal:  Front Vet Sci       Date:  2017-04-03

5.  Signal regulatory protein alpha (SIRPalpha) cells in the adaptive response to ESAT-6/CFP-10 protein of tuberculous mycobacteria.

Authors:  W Ray Waters; Mitchell V Palmer; Brian J Nonnecke; Tyler C Thacker; D Mark Estes; Michelle H Larsen; William R Jacobs; Peter Andersen; James McNair; F C Minion; Konstantin P Lyashchenko; R Glyn Hewinson; H Martin Vordermeier; Randy E Sacco
Journal:  PLoS One       Date:  2009-07-29       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.